Erasca (ERAS) Stock News

Erasca (Nasdaq: ERAS), a precision oncology company, reported significant progress in its RAS-targeting cancer therapy development program and Q2 2025 financial results. The company achieved key milestones with FDA clearance for two investigational new drug (IND) applications: ERAS-4001 (pan-KRAS inhibitor) and ERAS-0015 (pan-RAS molecular glue), both targeting RAS-mutant solid tumors.

The company maintains a strong financial position with $386.7 million in cash and equivalents as of June 30, 2025, expected to fund operations into H2 2028. Q2 2025 saw reduced losses with a net loss of $33.9 million ($0.12 per share), compared to $63.2 million ($0.29 per share) in Q2 2024. Initial Phase 1 monotherapy data for both drug candidates is expected in 2026.

Erasca announced FDA clearance of its IND application for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor for treating KRAS-mutant solid tumors. ERAS-4001 targets multiple KRAS mutations and wildtype KRAS while sparing HRAS and NRAS, potentially offering a better therapeutic window compared to pan-RAS inhibitors. The company also received IND clearance for ERAS-0015, a potential best-in-class pan-RAS molecular glue, both ahead of guidance. The BOREALIS-1 Phase 1 trial will evaluate ERAS-4001's safety, tolerability, and preliminary efficacy, while ERAS-0015 is being studied in the AURORAS-1 Phase 1 trial. Initial monotherapy data for both RAS-targeting programs is expected in 2026. The development addresses unmet needs for approximately 2.2 million people diagnosed annually worldwide with KRAS-mutant tumors.

Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, has announced its participation in two major investor conferences in June 2025:

1. Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 4 at 5:30 PM ET

2. Goldman Sachs 46th Annual Global Healthcare Conference (June 9-11) in Miami Beach, with a fireside chat scheduled for June 10 at 2:40 PM ET

Management will participate in one-on-one investor meetings at both conferences. Live audio webcasts will be available at Erasca.com/events, with replays accessible for 30 days after each event.

Erasca (NASDAQ: ERAS) reported Q1 2025 financial results and business updates, highlighting progress in its RAS-targeting cancer therapy programs. The company announced FDA clearance for ERAS-0015 (pan-RAS molecular glue) and IND submission for ERAS-4001 (pan-KRAS inhibitor), with initial Phase 1 monotherapy data expected in 2026 for both programs. Financially, Erasca reported $411.1 million in cash as of March 31, 2025, extending their cash runway to H2 2028. Q1 2025 showed improved financial metrics with net loss decreasing to $31.0 million ($0.11 per share) compared to $35.0 million ($0.23 per share) in Q1 2024. R&D expenses decreased to $26.0 million from $28.6 million, while G&A expenses reduced to $9.7 million from $10.3 million year-over-year.

Erasca (NASDAQ: ERAS) announced significant advancements in its RAS-targeting cancer therapy programs. The FDA cleared the IND for ERAS-0015, a pan-RAS molecular glue, and the company submitted an IND for ERAS-4001, a potential first-in-class pan-KRAS inhibitor. Both developments occurred ahead of schedule, with Phase 1 monotherapy data expected in 2026. The company also announced a strategic decision to seek partnership opportunities for naporafenib, extending their cash runway guidance from H2 2027 to H2 2028. ERAS-0015 targets approximately 2.7 million patients annually with RAS-mutant tumors, while ERAS-4001 addresses over 2.2 million patients with KRAS-mutant tumors. This strategic prioritization allows Erasca to focus on advancing its RAS-targeting franchise while maintaining over three years of projected cash runway.

Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will take place at the Encore Hotel in Las Vegas, Nevada. The company's management will deliver a presentation on Wednesday, May 14, 2025, at 2:35 PM Pacific Time and will engage in one-on-one investor meetings. A live audio webcast will be accessible at Erasca.com/events, with a replay available for 30 days following the presentation.

Erasca presented new preclinical data at the 2025 AACR Annual Meeting, highlighting advances in their RAS-targeting cancer therapy franchise. The company showcased two key compounds:

ERAS-0015, a pan-RAS molecular glue, demonstrated:

• 8-21 times greater cyclophilin A binding versus competitor RMC-6236
• Strong anti-tumor activity at lower doses
• Effective tumor tissue distribution

ERAS-4001, a novel pan-KRAS inhibitor, showed:

• Selective targeting of both mutant and wildtype KRAS
• Strong tumor growth inhibition in multiple models
• Promising results when combined with anti-PD-1 or cetuximab

Additionally, the company identified first-in-class direct SHOC2 binders, representing a new approach to block cancer-causing RAS/MAPK pathway signaling. These developments reinforce Erasca's position in precision oncology for RAS/MAPK pathway-driven cancers.

Erasca (NASDAQ: ERAS) has announced three poster presentations at the upcoming 2025 AACR Annual Meeting in Chicago, scheduled for April 25-30, 2025. The presentations will showcase the company's advancements in precision oncology, specifically targeting RAS/MAPK pathway-driven cancers.

The presentations will feature:

• ERAS-0015: A potential best-in-class pan-RAS molecular glue, to be presented on April 27
• ERAS-4001: A pan-KRAS inhibitor showing robust anti-tumor activity, scheduled for April 29
• Novel direct SMP complex inhibitors, representing a potential first-in-class approach to block the RAS/MAPK pathway, to be presented on April 28

All posters will be available on Erasca's website following the presentations.

Erasca (NASDAQ: ERAS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its RAS-targeting oncology programs. The company maintains a strong financial position with $440.5 million in cash and equivalents, expected to fund operations into H2 2027.

Key developments include the advancement of two promising candidates: ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), both scheduled to enter clinical trials in 2025. The ongoing Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma is progressing well, with Stage 1 randomized data expected in H2 2025.

Financial results show R&D expenses of $26.1 million for Q4 2024 and $115.4 million for the full year. The company reported a net loss of $32.2 million for Q4 and $161.7 million for the full year 2024, or $(0.69) per share.